Once again won the BIVA “Best Investment Value Award for Listed Companies”
2022-07-08

Once again won the BIVA “Best Investment Value Award for Listed Companies”

Once again won the “Most Valuable Pharmaceutical Listing Company” from Golden Hong Kong Listed Companies

Once again won the “Most Valuable Pharmaceutical Listing Company” from Golden Hong Kong Listed Companies

Recognized as the “All-Asia Most Honored Company”by the Institutional Investors Magazine

Recognized as the “All-Asia Most Honored Company”by the Institutional Investors Magazine

Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” and “Top 100 Corporate Taxpayers in Nanshan District”

Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” and “Top 100 Corporate Taxpayers in Nanshan District”

Invested in Destiny Pharma, and acquired assets of XF-73 and other antibacterial product portfolio in Mainland China and/or other countries or regions

Invested in Destiny Pharma, and acquired assets of XF-73 and other antibacterial product portfolio in Mainland China and/or other countries or regions

Continued to be the largest shareholder of Tibet Rhodiola Pharmaceutical with a total of 36.83% equity interest after completing the capital increase

Continued to be the largest shareholder of Tibet Rhodiola Pharmaceutical with a total of 36.83% equity interest after completing the capital increase